Voyager Therapeut (VYGR)
$11.88 0.40 (3.30%)
11:45 EDT VYGR Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 383.81M
PE Ratio -4.53
Volume (Avg. Vol.) 28,935
Day's Range 11.82 - 12.32
52-Week Range 6.26 - 16.53
Dividend & Yield N/A (N/A)
VYGR Stock Predictions, Articles, and Voyager Therapeut News
- From InvestorPlace
- From the Web
Young investors can leverage their extra time to bet on high-growth stocks that are likely to jump on developing trends.
These biotech stocks are set for a strong comeback as investors start to walk away from large-cap tech companies. Here's what investors need to know about each company.
Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.
3 Stocks to Watch on Tuesday: Mondelez International Inc (MDLZ), SBA Communications Corporation (SBAC) and Voyager Therapeutics Inc (VYGR)
Mondelez (MDLZ) and SBA Communications (SBAC) posted earnings, while Voyager Therapeutics (VYGR) issued an update on its Parkinson's drug.
From The Motley Fool
The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data
From Market News Video
Voyager Therapeutics Huntington's disease treatment put on hold by FDA; shares down 22% (NASDAQ:VYGR)
From Seeking Alpha
The company's Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington’s disease has been placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters.Voyager (NASDAQ:VYGR) expects specific feedback about this from the FDA within 30 days and plans to resolve whatever issues are noted.Shares are down 22% after hours.Source: Press Release
Navellier RatingsPowered by Portfolio Grader